Literature DB >> 21104297

Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles.

Maria Teresa Sartori1, Alessandro Della Puppa, Andrea Ballin, Graziella Saggiorato, Daniela Bernardi, Andrea Padoan, Renato Scienza, Domenico d'Avella, Giuseppe Cella.   

Abstract

The relationship between venous thromboembolism (VTE) and cancer is supported by several pathogenetic factors, including circulating microparticles (MP) originating from different cells and often bearing tissue factor. Since VTE often complicates the clinical course of patients with glioblastoma multiforme (GBM; WHO grade IV astrocytoma) and the role of MPs in these patients population is still not clear, this prospective study was conducted to evaluate the procoagulant activity of circulating MP (MP activity) in GBM patients. We enrolled 61 GBM patients undergoing gross-total or subtotal surgical resection followed by combined radio-chemotherapy; 20 healthy volunteers were tested as controls. Blood samples for MP activity and hemostatic profiles were obtained before and then 1 week and 1, 4, and 7 months after surgery. GBM patients had significantly higher mean MP activity levels than healthy controls before and 7 days after surgery. During the follow-up, MP activity levels became significantly lower 1 and 4 months after surgery (P = 0.007 and P = 0.018, respectively) than prior to surgery, but this decrease was only seen in the subgroup achieving complete tumor resection. MP activity levels increased in 7 (63.6%) of 11 patients who developed VTE. The different incidence of the increase in MP activity levels between patients with and without VTE was statistically significant (χ (2) = 4.93, P = 0.026; relative risk 1.38, 95% CI 1.03-1.86). GBM patients may have an increase in MP-associated procoagulant activity that could contribute to any prothrombotic states and increases the likelihood of VTE complications; this procoagulant activity drops during control of disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21104297     DOI: 10.1007/s11060-010-0462-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

Review 1.  The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review.

Authors:  L C Marras; W H Geerts; J R Perry
Journal:  Cancer       Date:  2000-08-01       Impact factor: 6.860

2.  Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer.

Authors:  P S Wells; D R Anderson; M Rodger; J S Ginsberg; C Kearon; M Gent; A G Turpie; J Bormanis; J Weitz; M Chamberlain; D Bowie; D Barnes; J Hirsh
Journal:  Thromb Haemost       Date:  2000-03       Impact factor: 5.249

3.  Venous thromboembolism and survival in patients with high-grade glioma.

Authors:  Ralph Simanek; Rainer Vormittag; Marco Hassler; Karl Roessler; Martin Schwarz; Christoph Zielinski; Ingrid Pabinger; Christine Marosi
Journal:  Neuro Oncol       Date:  2007-02-27       Impact factor: 12.300

4.  High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas.

Authors:  Carole Colin; Brigitte Voutsinos-Porche; Isabelle Nanni; Frédéric Fina; Philippe Metellus; Dominique Intagliata; Nathalie Baeza; Corinne Bouvier; Christine Delfino; Anderson Loundou; Olivier Chinot; Tamara Lah; Janko Kos; Pierre-Marie Martin; L'Houcine Ouafik; Dominique Figarella-Branger
Journal:  Acta Neuropathol       Date:  2009-09-23       Impact factor: 17.088

Review 5.  Microparticles and thrombotic disease.

Authors:  Pavel Davizon; José A López
Journal:  Curr Opin Hematol       Date:  2009-09       Impact factor: 3.284

Review 6.  Microparticles, thrombosis and cancer.

Authors:  Anat Aharon; Benjamin Brenner
Journal:  Best Pract Res Clin Haematol       Date:  2009-03       Impact factor: 3.020

Review 7.  Venous thromboembolism and prognosis in cancer.

Authors:  Alok A Khorana
Journal:  Thromb Res       Date:  2010-01-25       Impact factor: 3.944

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.

Authors:  David A Manly; Jianguo Wang; Sam L Glover; Raj Kasthuri; Howard A Liebman; Nigel S Key; Nigel Mackman
Journal:  Thromb Res       Date:  2009-10-24       Impact factor: 3.944

Review 10.  The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment.

Authors:  Anna Falanga
Journal:  Cancer Invest       Date:  2009-01       Impact factor: 2.176

View more
  21 in total

1.  Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.

Authors:  Nadim Tawil; Rayhaan Bassawon; Brian Meehan; Ali Nehme; Laura Montermini; Tenzin Gayden; Nicolas De Jay; Cristiana Spinelli; Shilpa Chennakrishnaiah; Dongsic Choi; Lata Adnani; Michele Zeinieh; Nada Jabado; Claudia L Kleinman; Michael Witcher; Yasser Riazalhosseini; Nigel S Key; David Schiff; Steven P Grover; Nigel Mackman; Charles P Couturier; Kevin Petrecca; Mario L Suvà; Anoop Patel; Itay Tirosh; Hamed Najafabadi; Janusz Rak
Journal:  Blood Adv       Date:  2021-03-23

Review 2.  Microparticle analysis in disorders of hemostasis and thrombosis.

Authors:  Micah J Mooberry; Nigel S Key
Journal:  Cytometry A       Date:  2015-02-20       Impact factor: 4.355

Review 3.  Spitting out the demons: Extracellular vesicles in glioblastoma.

Authors:  Gwennan André-Grégoire; Julie Gavard
Journal:  Cell Adh Migr       Date:  2016-10-13       Impact factor: 3.405

Review 4.  Microparticles in hemostasis and thrombosis.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Circ Res       Date:  2011-05-13       Impact factor: 17.367

Review 5.  Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence.

Authors:  Michael W Graner
Journal:  Annu Rev Genomics Hum Genet       Date:  2019-04-12       Impact factor: 8.929

Review 6.  Extracellular vesicles and intercellular communication within the nervous system.

Authors:  Valentina Zappulli; Kristina Pagh Friis; Zachary Fitzpatrick; Casey A Maguire; Xandra O Breakefield
Journal:  J Clin Invest       Date:  2016-04-01       Impact factor: 14.808

7.  Predictors of Venous Thromboembolism After Nonemergent Craniotomy: A Nationwide Readmission Database Analysis.

Authors:  Ian A Buchanan; Michelle Lin; Daniel A Donoho; Arati Patel; Li Ding; Arun P Amar; Steven L Giannotta; William J Mack; Frank Attenello
Journal:  World Neurosurg       Date:  2018-11-20       Impact factor: 2.104

8.  Thromboembolic disease in patients with high-grade glioma.

Authors:  James R Perry
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

9.  Mutant IDH1 and thrombosis in gliomas.

Authors:  Dusten Unruh; Steven R Schwarze; Laith Khoury; Cheddhi Thomas; Meijing Wu; Li Chen; Rui Chen; Yinxing Liu; Margaret A Schwartz; Christina Amidei; Priya Kumthekar; Carolina G Benjamin; Kristine Song; Caleb Dawson; Joanne M Rispoli; Girish Fatterpekar; John G Golfinos; Douglas Kondziolka; Matthias Karajannis; Donato Pacione; David Zagzag; Thomas McIntyre; Matija Snuderl; Craig Horbinski
Journal:  Acta Neuropathol       Date:  2016-09-23       Impact factor: 17.088

Review 10.  Extracellular Vesicles in Brain Tumor Progression.

Authors:  Esterina D'Asti; Shilpa Chennakrishnaiah; Tae Hoon Lee; Janusz Rak
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.